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Abstract
I perform an event study on 600+ patents awarded primarily to 20 leading biotechnology firms
and find significant changes in market values at the time of the awards. Adjusting for partial anticipation
of events, I estimate that core technology patents in highly contested research areas are expected to
generate between $13 and $21 million of economic value. They also generate spillover benefits for the
patentee’s rivals—presumably including knowledge transfers—valued at $3 to $6 million per firm.
Awardees may appropriate only half of private benefits, although I observe negative spillovers for some
high-profile awards. Most patents have no significant market impact.
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 Patents, Spillovers, and Competition in Biotechnology
David H. Austin∗
1.  Introduction
This paper analyzes stock market effects of individual biotechnology patent awards.
Incentives for firms to innovate depend partly on the potential value of the resulting patents and
their impact on rival firms. Patents also convey information about the abilities and prospects of
the firms, and they define intellectual property rights. Valued for all of these reasons, patents
have been an important way for biotechnology firms to raise equity capital and venture capital.1
However, by patenting, firms risk generating knowledge spillovers to rival firms. This paper
presents the first empirical measurement of the economic importance of patents for patentees and
their rivals.
Earlier studies have correlated patents with changes in the market values of firms by
using annual counts of successful patent applications as a proxy for the quantity of innovation in
the filing year. Such data are not suitable for my analysis, as the aggregation obscures
technological details that my study design requires. Because firms face different rivals for
different patents, those data also do not permit the examination of rival effects.
This study exploits in new ways the rich information contained in patent documents. In
addition to disaggregating the data, which allows me to explain patent value as a function of
content, I also analyze patent grants rather than applications. There is an obvious timing
difference in that it has taken an average of almost three years to process patent applications in
biotechnology.2 I use patent grants primarily because the market responds to them. They are
public information, widely and quickly disseminated.
                                                
∗  I received helpful comments and assistance from Bronwyn Hall, Suzanne Scotchmer, Zvi Griliches, Joshua Lerner,
Jean Lanjouw, Rebecca Henderson, Brian Wright, and two anonymous referees. I also thank participants in the
National Bureau of Economic Research (NBER) Productivity Group workshops and at the University of Chicago
Business School seminar on Economic and Legal Organizations. Remaining errors are my responsibility. I am
grateful to Resources for the Future for its generous financial support.
1 It often takes years for biotechnology firms to develop products that will generate consistent revenue streams. For
them, patents are an important way of signaling their prospects and attracting investment capital (Lerner 1995a).
2 The average lag is two years; the lag was nine months in my sample.Resources for the Future Austin
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Biotechnology is an ideal field for this analysis. New drug research is highly competitive,
and the firms place great importance on their patents; a priori it is not clear whether the patents
should help or harm rival firms. Trajtenberg (1990) suggests that individual patents play an
important role in the dynamics of industry sectors: “The whys and hows of cross-sectional results
regarding the structural characteristics of mature sectors ... cannot really be understood except in
light of how those sectors evolved into their observed equilibrium; ... [disaggregated] patent data
... seem to be particularly well suited to trace that process.”3 This observation is particularly apt
for biotechnology, where firms have relied heavily on patent protection and patents seem to have
played an important role in its evolving market structure.
Like Drosophila melanogaster—the fecund fruit fly that speeds genetic research—
biotechnology firms are prolific innovators. This study is organized around a mere 20 leading
firms, yet they won nearly 600 patents in the first decade of commercial activity. In the early
1990s, seven of them dominated national rankings of research intensity.4 Although this sample
does not represent patents as a whole, the market forces and cross-firm effects that it illustrates
may also exist in other industries.
I find that the market values of firms rise significantly when patenting occurs in contested
research areas, especially where several firms have had successful clinical trials. Core
technology patents in any of these areas appear to be valued between $13 and $21 million. Most
of these patents are also viewed as benefiting rival firms. Knowledge spillovers must flow most
readily between firms doing similar research, and here I show that these individual patents may
be a direct pathway, generating economic values of roughly $3 to $6 million per rival firm. Some
high-profile patents are viewed as harmful to rival firms and may have much higher own
valuations. Most of the other patents in the sample do not generate significant market effects.
The paper is organized as follows: Section II reviews the relevant economics literature.
Section III describes my theoretical model, which motivates the empirical analysis described in
Section IV. I discuss sample selection and data in Section V, and present the regression results in
                                                
3  Trajtenberg (1990), p. 215.
4 Five of the top ten American firms in 1991 R&D spending per employee were biotechnology companies—Biogen
(1), Genentech (2), Genetics Institute (4), Amgen (6), and Chiron (9)—as were six of the top seven companies in
1991 for R&D-to-sales—Centocor (1), Chiron (2), Biogen (3), Genetics Institute (4), Genentech (5), Immunex (7).
(Business Week 6/29/92, p.105). All of these firms are in my sample.Resources for the Future Austin
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Section VI. In Section VII, I use these results in simulating the theoretical model and deriving
implicit patent values. Section VIII offers concluding remarks.
2.  Literature Review
The empirical literature contains several different approaches to analyzing patent data.
Schankerman and Pakes (1986) and Lanjouw (1993) analyze European patent renewal fees in a
cross-industry setting and estimate patent values over time. Lanjouw (1998) develops a dynamic,
stochastic discrete choice model of optimal renewal decisions that recognizes that firms may
need to protect patents from infringement. Lanjouw finds that, on average, the annual value of
patent protection is roughly 10% of the associated R&D expenditures and, as in the two earlier
studies, the distribution of patent values is highly skewed.
Renewal fee data are useful for distinguishing between high- and low-valued patents, and
for estimating the time path of a patent’s value. A patent will not be renewed if the fee exceeds
its value. The fees, however, are very low relative to the values of important patents, so although
their identities can be inferred from the renewals, their values cannot be estimated directly.
Analysis of the U.S. data has not been possible because renewal fees were instituted only
recently. See Lanjouw, Pakes, and Putnam (1996) for a detailed survey of these studies.
Several papers link individual patent characteristics to the private value of the patent.
Lerner (1994) finds that the breadth of patent protection is associated positively with firm
valuations in a set of privately held, venture-backed biotechnology firms.5 Austin (1993)
identifies a small, positive effect of patent breadth on the market values of a set of publicly
traded biotechnology firms by using a similar measure of breadth.
Other studies have examined the relationship between the annual market returns of a firm
and the total patent applications that eventually result in patents that the firm filed that year.
Griliches (1981) finds that surprises in a firm’s annual total are related positively to changes in
its market-to-book value ratio and that “a successful patent is worth about $200,000” (Griliches
1984). Because U.S. patent applications are not announced, these studies are inconclusive about
whether patents or the underlying research or innovations are driving observed changes in firm
                                                
5 Lerner’s patent-scope proxy is a function of the number of technological areas under which the patent is classified.Resources for the Future Austin
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value.6 For instance, Pakes (1985) argues that when a firm receives a patent it “indicates that
events have occurred that increase the firm’s market value by $810,000.” Griliches, Pakes, and
Hall (1987) find a strong cross-sectional relationship between the annual patent applications of
firms and changes in market value. They also find a weaker but significant relationship between
year-to-year changes in successful patent applications and returns to equity. See Hall (1999) for a
recent survey of this literature, a central conclusion of which is that patents are a proxy for R&D
success, that they add information beyond measures of total R&D activity, and that this
information has a positive market value.
Empirical research on the effects of patents on other firms has focused on R&D spillovers
rather than market effects. Jaffe (1986) notes that a firm’s number of patents per dollar of R&D,
and its returns to R&D, tend to be higher if it is “close” to other research firms in technology
space. Megna and Klock (1993) find that patent stocks for 11 rival semiconductor firms have
negative effects on the market-to-book value ratios for other firms, while their R&D
expenditures have positive effects. Jaffe, Trajtenberg, and Henderson (1993) find geographically
localized patterns to R&D spillovers, as measured by patent citations. Finally, Cockburn and
Henderson (1994) find that R&D investment in the presence of rival firms is not winner-take-all.
Rather, own research productivity is correlated positively with the research outcomes of rival
firms. They interpret this finding as evidence for widespread R&D spillovers. Most of these
studies are consistent with firms benefiting from the patents of rival firms, though there is also
evidence that patent rights can impose costs on rival firms. Griliches (1990) contains a thorough
survey of the earlier empirical literature on patent value.
3.  Model
This section describes the general theoretical framework underlying my empirical
analysis. I develop a model of stock market excess returns in which the prior expectations by
investors about patentable research, and the odds of patenting by firms in the face of
competition, are capitalized into the firms’ stock prices. I simulate the model that assumes a
                                                
6 The Japanese and European patent offices publish pending patent applications 18 months after the earliest filing
worldwide. Because U.S. firms often file overseas for patents on significant innovations, the domestic stock markets
may develop expectations about corresponding U.S. patents. Working papers in circulation may also yield clues.
Applicants for U.S. patents have a year to file after a paper is circulated. Applications in Europe and Japan must
precede publication of the paper, and the one-year anniversary of the earliest worldwide filing.Resources for the Future Austin
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range of values for the unobservable priors and yields estimates of private patent value and
spillover effects implicit in the excess returns.7
Consider N firms racing for a patent. If the identities of the firms are known, then
investors’ priors about each firm’s likelihood of winning the patent, and about the value of that
patent, are reflected in the firms’ pre-patent stock prices.8 Let p be the market’s prior probability
that a patent will issue, 0 ≤  p ≤  1.9 If the research is not observed, or is believed not to be
patentable, then p = 0. If a patent is anticipated, investors’ symmetric priors that it will go to a
particular firm equal 1/N. Asymmetric expectations are also permitted.
Let a patent’s expected present discounted value, on the day it issues, be V ￿ 0, the net
present value of the stream of rents from products embodying the innovation, plus any resulting
revaluation of the firm’s other assets. Some of them—especially intangible ones—may
complement the innovation or be revalued as the patent updates the firm’s quality signal. Rents
are net of revenues in the absence of the patent.10
A new patent may raise or lower the values of the (N - 1) rival firms. Their values will
decline if investors expected that the patent might be issued and if the expected own value share
V/N dominated the expected net spillover benefits share C(N-1)/N; that is, the net effect (benefits
less costs) of losing times the odds of losing. A patent may impose both costs and benefits on
rival firms and raise R&D costs by foreclosing research avenues, or induce infringement
litigation, but the patent discloses knowledge that might complement the rivals’ research. The
sign of the rival effect is an empirical issue.
If investors’ prior probabilities are symmetric with respect to the N firms, then as the
patent is issued, each firm’s market value will reflect patent expectations according to:



















                                                
7 I use the term “spillover” to refer to any economic benefit accruing to another firm due to a patent and not limited
to knowledge spillovers.
8 Many biotech innovations are discoveries of genetic sequences for known proteins or of processes for synthesizing
natural proteins, and thus may be anticipated to a degree. It is plausible that investors know who is racing because
the information is published in BioScan.
9 Because p is not observable, I ignore its possible time-dependency.
10 Many biotech patents issue before FDA approval is won (or requested), and uncertainty about that process affects
the valuations of those patents. Most biotechnology products are protected by a host of patents.Resources for the Future Austin
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The premium reflects the expectation p that a patent will issue, times the patent’s expected effect
on each firm. Note that C < 0 implies a benefit to the other firms.11
Once investors learn the outcome of the patent race, the winner and losers are revalued
according to expressions (1) and (2) below. Unanticipated information creates excess returns, or
differences between predicted and observed prices. For the patentee, these equal:






















The change in the patentee’s market value consists of the reversal of the rival effect in C and the
addition of the remaining patent value V, net of the portion already capitalized.12
The values of the losing firms will change according to:

















The first term reflects a firm’s failure to win the patent, and the loss of the market
premium given it might win. The second term gives the expected cost of its rival’s patent, net of
the portion already capitalized. For unanticipated patents, p = 0 and the excess returns are simply
V for the patentee and C for each losing firm.
As N is the only observable parameter in the model in the simulations that assume values
of p to solve the equations for V and C given the data.
If investors have (correct) asymmetric priors about the patentee, this model will
understate V and C, which would be capitalized more fully than implied by the symmetric model.
If investors correctly put extra weight 1 < α  < N on the eventual patentee given that a patent will
issue, priors for the other firms’ collective chances of winning will drop to (N – α )/N. Adding an
asymmetric prior α , the model becomes:
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11 “C” is a mnemonic for the “cost” of losing a patent.
12 V could be negative if the patent disappoints expectations of its probable scope or content.Resources for the Future Austin
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To solve for V and C in the asymmetric model, α  must be simulated along with p.
The asymmetric model applies to several research areas in the data. For instance,
Genentech has dominated competitors in research on human growth hormone and tissue
plasminogen activator, a treatment for heart attack and stroke. In simulations I subject α  and p to
sensitivity analysis.
4.  Empirical Framework
These models suggest that excess returns depend on patent values, expected effects on
rivals, the number of rivals, and the identity of the patentee (own or rival). I assume that values
and rival effects depend on characteristics of the patents, and I have data on presence or absence
of recombinant DNA (rDNA) content; breadth; the protein with which the patent is associated, if
any,13 and the number of firms active in the research field. I interact these characteristics with
indicators of patentee identity relative to the firm being observed.
Excess returns take the following form:
EXCESS RETURN = F((rDNA, breadth, significance; protein; N)*(OWN; RIVAL; NEUTRAL))
The first three characteristics in this equation enter the model in interaction with the
fourth, a “protein” indicator variable that controls for patents on some aspect of protein
synthesis, including genetic sequences. Proteins researched by only one of the sampled firms are
not captured by this variable, which picks up about 15% of the patents. The OWN, RIVAL, and
NEUTRAL effects also refer only to these protein patents, as those relationships are defined in
terms of the proteins. The own effects of all “nonprotein” patents are captured by the intercept
term. I expect the positive own effect of a protein patent is greater than the effects of its other
patents, which do not relate directly to products.
Slightly more than half the patents in the sample have rDNA content.14 Others cover
equipment, procedures, novel drug use, or nonrecombinant chemical discoveries. I hypothesize
                                                
13 Biotechnology drugs are based on proteins, or amino-acid sequences.
14 See the Data section for definitions and sample statistics.Resources for the Future Austin
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that own rDNA patents are more valuable because they involve core technologies. Their
marginal effect on rival firms is indeterminate a priori; rDNA patents often include codified
amino acid sequences that may facilitate knowledge spillovers.
The greater the scope or breadth of a patent, the more intellectual property it controls. I
expect patent breadth to be associated positively with own returns and negatively with returns to
rival firms.
The third variable controls for “significant” patents and related mean shifts in the
dependent variable. This variable does not reflect any particular patent characteristic. The
empirical literature shows that patent values are highly skewed, with very few high-value
patents. I proxy for a significant patent by whether or not it was described in the Wall Street
Journal (WSJ)15 and expect the own WSJ effect to be positive. Many of these patents are major,
blocking patents on gene sequences or production processes, and I expect their effect on rival
firms to be negative.16
Finally, N is the number of competitors in each research area. As N increases, own effects
should increase and rival effects should shrink in absolute value. This follows from the
theoretical model.17
As implemented econometrically, the dependent variable is the excess return from the
standard Capital Asset Pricing Model (CAPM), expressed in percentage terms.18 The model
assumes explicitly that patent value is independent of firm size. Firms have varying levels of
resources for exploiting patents but can license them to the highest bidder. All else equal, a
patent will affect more strongly the stock price of a more highly leveraged firm, but there are no
                                                
15 A referee has suggested that this variable may be endogenous with excess returns. In my sample, about one in
four WSJ patents gave own, first-day excess returns above +2%, twice as frequently as with other protein patents,
but negative or zero returns were just as likely among WSJ patents. I will not emphasize the WSJ results, treating
them, with caveats, as a possible upper-bound on outlier valuations.
16  See the appendix for a description of the WSJ patents.
17 Differentiating (1) and (2) with respect to N, it is clear that the larger is N, the greater the surprise that a particular
firm patents—meaning higher own excess returns—and the less of a surprise that other firms do not patent,
minimizing those excess returns.
18 Patent grants are announced immediately, and a three-day event window captures their full impact. Even before
web browsers, same-day information about new patents could be retrieved electronically. To match the dependent
variable I normalize the independent variables by pre-event firm value, logged to give a better fit and reduce
heteroskedasticity (which is inversely proportional to firm size). Normalizing the intercept term merely inflates the
other coefficients without changing the results.Resources for the Future Austin
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significant cross-firm differences in bond-to-equity ratios here, because the firms did not use
debt financing.
Thus, I estimate
Rit = δ 0 + δ ν ⋅ Dν t + uit
ν ∑           t = 1, …, T, (3)
where  it R  is the firm i excess return from an event at time t, and the  t Dν  are the interaction
dummies. The  t Dν  also include an indicator variable to control for events subsequent to joint
venture or licensing agreements between erstwhile rivals;  it u  is a mean zero random error, and
0 δ  and  ν δ  are parameters to be estimated.
The dependent variable  it R  is the time t CAPM residual:
Rit ≡ r it − rft () − ˆ  α  it + ˆ  β  it r mt − rft () ( ) ,( 4 )
Rit is measured from one trading day prior to the event to two days after it.19 I estimate  it α ˆ  and
it β ˆ  by fitting the CAPM to 244 days of data ending the fifth trading day before the event;  it β ˆ
estimates the volatility of firm i’s stock relative to the S&P 500. Finally,  it r  is the return on
shares in firm i at time t;  ft r  is a risk-free rate of return (inflation-adjusted 30-day T-Bill rate);
and  mt r  is the return on the value-weighted Nasdaq index. The CAPM also includes a serially
uncorrelated, mean zero random error term.
5.  Data
The study design requires the identification of competing firms, which is a manageable
task because the study involves only one industry. Biotechnology is a good subject because the
firms patent fervently and defend their claims.20 The results, though particular to biotechnology,
suggest that patents are not anticipated highly, and that this type of event study can be repeated
for other industries.
Among the 20 leading biotechnology firms in this study, there has been competition in at
least 17 research areas from which every major biotechnology drug so far has originated. The 20
                                                
19  See Brown and Warner (1985). I use the Nasdaq composite index as the market measure, because all of the firms
in the sample traded in that market. In the late 1980s, Genentech switched to the NYSE.
20 There has been an extraordinary amount of patent litigation in biotechnology (Lerner 1995b).Resources for the Future Austin
10
firms were selected because, as of December 1988, they were the most highly valued, publicly
traded firms.21 The date is midway between the last of three early waves of initial public
offerings in biotech (IPOs), in 1986, and the end of the sampling frame in 1991.22 By 1992 these
firms had received 565 patents; the data include another 69 awarded for competing—or
complementary—innovations by outside firms and organizations. Stock price data come from the
Center for Research in Securities Prices (CRSP).
These data span the first decade of commercial biotechnology. Innovations from that time
have been important in determining the competitive positions of these firms. Dominant in cross-
industry rankings of R&D intensity, the firms also dominate biotech patent-holder lists. Almost
half of nearly 800 patents awarded by 1988 to more than 100 biotech firms belong to a firm in
my sample.23
BioScan, a quarterly trade publication, reveals that progress has been unequal over the 17
research competitions. Some have produced FDA-approved drugs, while others have stalled in
clinical trials. For nine areas, at least two rivals had reached the final Stage III of clinical trials by
the end of the sampling period. RIVAL and NEUTRAL effects are sharper in those areas, and, in
terms of patents, firms have been much more productive. Seventy-six percent of the protein
patents in the sample—and about 80% of rDNA, broad, or WSJ patents—were awarded in these
areas. I limit the regression analyses to the nine proteins.24
I identify patents with specific proteins by keyword searches of patent titles and abstracts,
and company press releases. This technique matches 121 patents, or 21%, with one of the 17
protein families—an average of 7 patents per protein. The other 444 patents either relate to
proteins only one firm was researching or are not associated with any protein.25 The same
keywords identify the other 69 patents.
                                                
21 See Table A1 for the list of the 20 firms. I limited the sample to firms with a primary focus on pharmaceutical or
medical diagnostic products.
22 Sampled firms went public, mostly in 1981, 1983, and 1986.
23 In Lerner’s 1994 list, the 20 firms in my sample had 345 patents by 1989 and by 1992, two of them, Genentech
and Cetus, each had more than 100. The other 18 firms averaged 16 patents.
24 See Table A2 for the 17 proteins for which the sampled firms have competed, and the 9 featured in the results.
25 For example, patent 4824641, awarded to Cetus for “carousel and tip.” In all, about 30 or 40 proteins were being
pursued by about 250 commercial firms. (U.S. News and World Report, 11/24/86, p. 52).Resources for the Future Austin
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None of the patents cover all aspects of a protein molecule or of its uses.26 None is linked
to more than one protein, and no protein is covered by only one patent. When a “protein patent”
is issued, I observe stock prices of the patentee, its rivals, and the remaining neutral firms. Rivals
are in-sample firms that are active in research on the protein to which the new patent relates.27
For patents not related to any of the nine featured proteins, I measure own effects only, because
rivalries are not defined.
U.S. patents are issued only on Tuesdays, many on the same day. Following standard
practice, I drop most such patents.28 The remaining 416 generate 1,670 “events.” Most patents
generate a single own event, whereas protein patents generate up to 20 events, one per firm. The
overlap exclusions slightly favor protein patents, which generate about 26% of OWN events.
Table 1 reports mean excess returns on 86 protein patents and 59 nonoverlapping,
ancillary-search patents. These generate 86 OWN, 480 RIVAL, and 856 NEUTRAL events.29 An
average of 4 to 5 firms compete for each protein, which leaves as many as 16 neutral firms,
depending on their IPO dates. It is not surprising that returns are highest for own, protein patents,
whereas a RIVAL mean of 0.6% hints at positive spillovers from these patents.30 I investigate this
finding in greater depth in the regressions. The table also shows mean returns from the 248
patents not associated with a study protein.
                                                
26 This is the root cause of much biotech patent litigation. For instance, in 1987, two U.S. patents issued on
erythropoietin (EPO) a commercially valuable, natural enzyme that stimulates red blood cell production. First,
Genetics Institute received a patent on a synthesizing method, then Amgen patented EPO’s genetic sequence. Each
patent potentially blocked the other. With huge returns at stake, the firms litigated. Amgen prevailed four years later
and, thanks to EPO, became the world’s largest biotech company.
27 Some rivalries are modulated by joint-venture or other agreements. BioScan lists these, and I control for them in
the regressions.
28 I do not exclude OWN or RIVAL events that coincide just with NEUTRAL events. I also exclude NEUTRAL events and
“non-protein” patents occurring within one week of OWN and RIVAL events, which may influence them. These
exclusions make no qualitative difference.
29 Ancillary patents generate no own events.
30 As a check on the model specification, randomly selected days yield a mean-zero excess return as expected.Resources for the Future Austin
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Table 1. Mean Percent Excess Returns to Patent Grants
Three-day event window





1670 0.61 6.05 –24.4 32.9
Not protein patents:
OWN 248 0.63 5.89 –21.8 21.5
Protein patents:
OWN 86 1.25 7.02 –24.39 32.88
RIVAL 480 0.60 5.44 –16.03 29.56
NEUTRAL 856 0.55 6.32 -23.11 31.18
The regressions estimate shadow values for patent characteristics—breadth, rDNA
content, and a WSJ announcement—that I described earlier. I define 36 patents as “broad,”
which means they belong to three or more international classification (ICN) categories.31 There
are 48 rDNA patents, which are those classified into special categories U.S. 930 or 935 for
“recombinant DNA” or “genetic engineering.” Because these categories were not defined until
1984, they miss several patents. Finally, 16 patents, about 5% of the final sample, were discussed
in the WSJ. This press coverage, usually just a few inches of column space, typically occurred
the day after the patent issued. Several patents were discussed later or were given more space.32
                                                
31  An ICN-based measure is validated in Lerner (1994) for four or more categories. This stricter definition applies
to fewer than 10% of the protein patents, only one of which is not also an rDNA or WSJ patent.
32 The WSJ criterion captures four patents from Lerner’s (1994) list of 13 “seminal” biotechnology patents. Twelve
of those patents issued to firms in my sample. Not all of them are protein patents, which leaves too few patents in
the regression sample for meaningful statistical analysis. If one ignores possible overlapping events, own excess
returns for the twelve average 5.1%, while average rival returns are zero.Resources for the Future Austin
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Figure 1. Cross-classification relationships for 86 protein patents
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Figure 1 describes the relationships among these variables. The left column shows that of
48 rDNA patents, 23 are broad patents, 2 were announced in the WSJ, 7 belong to all three
groups, and 16 are rDNA only. The next two columns can be read the same way. The final
column shows that 25 of 86 protein patents are not broad, have no rDNA content, and were not
announced in the WSJ. These groupings are for all 17 proteins; results for the subset are almost
identical.
6.  Regression Results
The regressions begin with a simple specification distinguishing between only so-called
protein patents and the other patents.33 The protein dummy is interacted with indicators of firms’
identities vis-a-vis the patentee, because stock price reactions are observed for every firm when a
protein patent is awarded.
Table 2 presents these results. Regression (I) essentially reprises Table 1, although it is so
only for research areas that had two firms at or beyond Stage III. The OWN coefficient shows that
these patents are significantly more highly valued than other biotech patents, which raises the
market values of the patentees by an average of 1.85%, or $8.3 million, for these firms.34 This
effect, significant at the 1% level, is large but it understates the true valuations. I derive full,
implicit values in the next section.
These patents seem also to produce positive spillover benefits for other firms. NEUTRAL
captures the effect of patents awarded in areas unrelated to a firm’s own research. When a
protein patent issues, the market values of neutral firms increase by $0.6 million on average,
which is statistically significant at the 7% level. This finding could reflect expected knowledge
spillovers, but it might also be a sign that the patents, in general, have increased investor
confidence in biotechnology firms.35
                                                
33 For these regressions, the latter group includes patents from the eight research areas in which one or fewer firms
had reached Stage III in clinical trials. This boosts membership to 269 patents while reducing the number of protein
patents to 65. Cf. Table 1. The ancillary patents are included in these regressions but do not qualitatively affect the
results.
34 I back these numbers out by de-normalizing the regression coefficients. Models including N in the interactions, as
suggested by the theoretical model, produce identical results but do not fit the data as well and exhibit greater
heteroskedasticity.
35 Revaluation of “neutral” firms may drive Mitchell and Mulherin’s (1994) finding of a small, positive relationship
between the number of stories (of all types) appearing in the WSJ and aggregate returns to securities that day. SuchResources for the Future Austin
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The RIVAL effect gives evidence that suggests positive spillovers to direct competitors of
a rival patentee. The effect is larger than the NEUTRAL effect, but is not estimated as precisely:
When a rival firm wins a patent, the values of the other firms active in the same area increase by
an average of $1.7 million.36 The difference between rival and neutral effects may reflect the
greater value of spillovers to competitors, for whom the knowledge is more relevant. Differences
with the own effect are statistically significant at 5%.
I control for erstwhile RIVAL events that are subject to joint venture or patent licensing
agreements. The sign and magnitude of the joint venture (JV) effect are consistent with these
agreements, in the sense that the effect on a firm’s market value of a JV partner’s patent or a
licensed patent is almost identical to the effect of the firm’s own protein patents.
Limiting the firm effects to nine research areas and paring away the eight others in which
less progress had been made boosts the coefficients by 25%–35% compared with the full 17
research areas. The proximate reason why these patents are more valuable could be because
innovations in these nine research areas are closer to market. Possible reasons for that, in turn,
might be because those markets are bigger, consumer willingness to pay is higher, or the
innovations offer greater quality improvements over conventional substitutes.
Although model (I) is significant statistically, its adjusted R-squared is very small.
Distinguishing between OWN, RIVAL, and NEUTRAL effects explains less than 1% of the variation
in excess returns across firms and patents. The CAPM model, of which excess returns are the
residuals, explains about 70% of the variation in stock prices. Patents significantly affect prices,
but these models explain at best less than 3% of residual variation.
                                                                                                                                                            
revaluations are acknowledged explicitly, within limits, in biotechnology: “There are only so many times you can
[r]evalue a whole industry based on one or two companies’ news,” says Rick Stover, biotech analyst … .”
36 Despite its smaller coefficient, the rival effect is greater than the neutral effect because in the nine research areas,
the firms are larger than average. The patentees are worth $420 million on average; rival firms, $276 million—thus,
larger firms have also patented more often in these races; and neutral firms, $85 million.Resources for the Future Austin
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Table 2.  Effect of Biotechnology Patent Grants on Firm Values
Dependent variable: firm excess returns












INTERCEPT 0.125 0.124 0.130 0.123 0.127
(0.212) (0.212) (0.212) (0.211) (0.210)
OWN 23.942 *** 19.058 * 2.299 7.616 -15.338
(8.457) (10.93) (13.166) (9.292) (13.742)
RIVAL 6.181 8.650 -0.755 7.933 * 0.867
(4.000) (5.000) (6.449) (4.000) (6.000)
NEUTRAL 6.883 * 9.023 * –3.273 4.286 -5.065











NEUTRAL-rDNA 14.330 ** 13.383 **
(6.479) (6.447)
OWN-WSJ 81.349 *** 82.497 ***
(19.778) (19.733)
RIVAL-WSJ –21.280 * –21.648 *
(12.551) (12.520)
NEUTRAL-WSJ 22.944 ** 21.768 **
(9.273) (9.267)
JV AGREEMENT 18.217 17.508 21.305 18.808 21.853 *
(13.339) (13.37) (13.389) (13.250) (13.299)
N 1667 1667 1667 1667 1667
Adj R-sq 0.0047 0.0039 0.0098 0.0182 0.0233
F 2.971 1.924 3.359 5.423 4.983
Prob > F 0.0185 0.0622 0.0015 0.0001 0.0001
Notes: Heteroskedasticity-consistent standard errors in parentheses
Firm effects are for patents in nine areas with multiple firms in Stage III clinical trials
RHS variables interacted with [ln(firm value)]
–1
* significant at 10% level; ** 5%; *** 1%Resources for the Future Austin
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Model (II) shows that broad protein patents may be more valuable to the patentee than
narrow ones and that they may be less helpful to other firms, although these incremental effects
do not differ significantly from the effects of all protein patents. All else equal, broader property
rights restrict the utility of knowledge spillovers and enhance the appropriateness of a patent, and
these results are consistent with this. F-tests show that the OWN effects of broad patents are
significant at the 1% level and also different from their effects on RIVAL firms and NEUTRAL
firms at 5%.37
Model (III) examines rDNA patents and reveals that the interesting effects in model (I)
are due to these core patents. Model (III) also explains twice as much variation in the dependent
variable. When rDNA patents issue, market values increase by $12.6 million—more than 50%
larger than the model (I) estimate, which is now seen to average high- and low-value patents.
The NEUTRAL effect is one-third larger at $0.8 million, as is the RIVAL effect, here $2.5 million.
The incremental effects of the OWN and NEUTRAL rDNA coefficients are significant at 5%, while
the RIVAL rDNA coefficient is not significant at conventional levels (tail probability 14%). F-
tests confirm that total effects of all three events, combining the protein and rDNA coefficients
and the intercept, are significant statistically (RIVAL at 5%, the other two at less than 1%) and
that, once again, OWN effects are the largest by a significant margin.
Regression (IV) controls for mean shifts from blockbuster patents. One in five of the
protein patents in the nine featured races that were noted in the WSJ, usually the day after they
issued. As Figure 1 shows, more than half of the WSJ patents are broad and have rDNA content.
Own firm values increase an average of $29.4 million for WSJ patents, which is nearly two-and-
a-half times the rDNA effect and is strongly significant at the 1% level. The effect for NEUTRAL
firms is also more than twice as large, at $1.9 million, and is also highly significant. These
effects differ in degree from their counterparts in regression models (I)–(III), but the RIVAL-WSJ
effect differs in kind. When a rival wins a WSJ patent, a firm’s value declines by an average of
$2.5 million, or almost $4.5 million relative to the NEUTRAL firms in the sample. The RIVAL
coefficient is significant at the 10% level. F-tests for differences between all of the effects are
significant at the 1% level.
                                                
37 The slightly stronger definition of breadth used by Lerner (1994) should produce larger effects, but they cannot be
implemented here due to sample-size limitations.Resources for the Future Austin
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Many of the WSJ patents have given the patentee a monopoly or a strong competitive
advantage in selling the embodying drug. The RIVAL effect may indicate that the patents are
viewed as winner-take-all prizes with market-power implications that are expected to dominate
any spillover benefits. The WSJ criterion accounts for almost four times as much variation as the
basic model.
First-day, pre-publication reactions to WSJ patents are no stronger than average, and this
criterion does not appear endogenous. The valuations could reflect excessive responses to the
WSJ events, subject to later correction, but the valuations are also consistent with the high status
of most of these patents. The WSJ results do not represent biotech patents as a whole, and caveats
about the WSJ results should be kept in mind.
The final model (V) includes both the rDNA and the WSJ effects, which overlap only
somewhat. The interaction effects are changed little from models (III) and (IV), and they imply
that the effect of WSJ patents with rDNA content is about 16%, or $4.8 million, greater than for
other WSJ patents. The explanatory power of model (V) is the largest of the five, by about 30%.
These results indicate that certain, well-defined kinds of biotechnology patents induce
significant market responses of magnitudes consistent with characteristics of those patents. In the
next section, I simulate the theoretical model to derive implicit market valuations for these
patents, given that they may be anticipated partially. Event analysis of corresponding patent
applications yields no evidence of excess returns, even by using longer event windows. If U.S.
patent applications are a source of anticipation about pending patents, the information either does
not coincide with the event or is treated as highly uncertain.38
7.  Simulations
The theoretical model (see Section III) comprises two equations in three unknown
parameters, including returns V from winning a patent and C when a patent is awarded to another
firm. Here, I use trial values for the third unknown parameter, p, prior expectations by investors
that a patent will issue, to solve the model given observed market effects.
                                                
38 For the application event analysis, I use a 10-day window (–5, +5). Anticipation could come from firms
announcing their patent applications or early notification of pending patents, which may precede a patent by several
months. In my sample, it took an average of 34 months for the patent office to process a successful application,
meaning that overseas applications, if filed simultaneously, would be published on average 16 months before the
U.S. patent issues.Resources for the Future Austin
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Subtracting model Equation (2) from (1) yields C = OWN EFFECT - RIVAL EFFECT - V,
which by substitution leads to a single expression in V:
  () N N p OE N p RE p N V − − ⋅ ⋅ − − ⋅ ⋅ = − ⋅ ⋅ ) 1 ( ) 1 ( ) 1 (( 3 )
OE and RE are observed excess returns: OWN and RIVAL, respectively. N is the number of firms
in a research area. I assume N = 6.6, the average number in my sample over nine areas. Algebra
yields the implicit valuations reported in the top-half of Table 3 for low, medium, and high
values of p.
The alternative model assumes that investors put extra weight on the eventual winners’
odds of patenting correctly. Manipulating (1’) and (2’) does not yield tidy expressions, but the
model can be solved for V and C when an assumption is made about the weight α . Simulations
show that the results are not very sensitive to this parameter.  Table 3 presents the basic model,
which corresponds to the equal-weighting case α  = 1, and it presents α  = 5, which is close to its
maximum allowable value of N.
Table 3. Average Patentee Benefits, V, and Rival-Firm Costs (benefits), C







(III) rDNA patents (IV) WSJ patents
α α α α  = 1 p V C V C V C
All firms equally prior-weighted
0.1 $8.60 ($2.00) $13.05 ($2.95) $29.65 $2.35
0.5 $11.00 ($4.40) $16.63 ($6.53) $31.65 $0.35
0.9 $32.60 ($26.00) $48.87 ($38.77) $49.64 ($17.64)
Patentee prior weight α /N, all other firms weighted (N – α )/N, for N = 6.6
α α α α  = 5 p V C V C V C
0.1 $9.03 ($1.92) $13.71 ($2.83) $31.74 $2.72
0.5 $14.11 ($3.84) $21.39 ($5.68) $46.73 $3.05
0.9 $42.68 ($24.20) $64.30 ($36.02) $98.51 $8.91
$ millionsResources for the Future Austin
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If patents are highly anticipated, their true market values are much higher than the
observed changes in firm valuations. Excess returns reflect only the portion of patent value not
already capitalized into stock prices before the event, or 10% when p = 0.9. With equally
weighted firms, the present discounted own value of a protein patent with rDNA content would
average $49 million. Implausibly, expected spillovers per rival would be nearly as high. If the
patentee’s identity were also highly anticipated, the implicit valuations of these patents would be
about 30% higher, although spillovers would be a little lower. To put this figure in perspective,
valuing all of the protein patents at $64 million—for α  = 5, p = 0.9 and rDNA content—and the
others at $0, the sampled firms’ patent portfolios would have been worth between one-third and
one-half of the firms’ then-market capitalizations.
Startup biotech firms are often valued largely for their intangible assets. Attributing $800
million of Genentech’s then-$2 billion market capitalization to its patents might be defensible if
one assumed revenues would be $0 without them. Such high valuations depend on aggressive
assumptions, however, and finding comparable rival benefits is not so easily defended.
For lower values of p, the estimates are more conservative and less elastic with respect to
p and α . At p = 0.1, they are fairly insensitive to α  and average about $9 million for all own
protein patents, or about $13 million for just rDNA patents. For p = 0.5, the estimates vary a
little more with α  and range from $11 to $14 million or $17 to $21 million, respectively. From
this calculation, I conclude that $9 million is a conservative estimate of protein-patent values.
Those lacking rDNA content are worth much less, whereas my central estimate for the rDNA
protein patents is about $17 million.39
Even at $9 million, own patent values would be tenfold the largest estimate in the
literature. There are several possible reasons for this estimate. It is likely that patents are
unusually important in biotechnology, whereas earlier studies are based on many industries and
do not include biotech. Also, averaging annual changes in firm value over many patents
inevitably produces a low estimated value per patent, because I, and others, show that most
                                                
39 The lower p assumption produces more plausible value and appropriability estimates, and it is also more
consistent with the significant NEUTRAL effects in the regressions, which cannot be explained by surprises in the
identity of the patentee.Resources for the Future Austin
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patents are not very valuable. Finally, the patents in Table 3 are for innovations in core
technology and are even more valuable than average biotechnology patents.40
For p = 0.1, and regardless of α , spillover benefits for rival firms are about $2 to $3
million, or $3 to $6 million for rDNA patents, which account for no more than about one -fourth
the level of corresponding own values. Corresponding estimates for neutral biotechnology firms,
not shown, range from $0.7 to $1.0 million. I observe more than five rivals per patentee, which
suggests that the patentees appropriate somewhat less than half the total benefits of their patents.
On average, though, only two or three of the rivals are in the firm sample, where spillovers may
be greater. Outside firms include a competitive fringe, which may benefit less from spillovers;
and public research institutes such as National Institutes of Health, where incentives to exploit
spillovers may be lower than in the private sector. Thus, appropriateness may be higher than that
strictly implied by the spillover estimates.
8.  Summary and Conclusions
Patents generate rents for patent-holders and may impose externalities on their rivals.
This paper presents the first direct empirical evidence on the private economic value of these
effects. I find that new patents often induce significant firm revaluations, especially for the
patentee and its competitors. This paper demonstrates that as a rule, patents are not highly
anticipated and that an event study of patent grants can be an appropriate way to value them.
I perform the study on an original sample of more than 600 biotechnology patents
awarded to primarily 20 leading firms. I create a theoretical framework for interpreting the
results by modeling how expectations about future patents and patent-holders affect market
values. My estimates of the underlying patent valuations are, however, relatively insensitive to
parametric assumptions about these prior expectations, within a range of plausible values.
Depending on those assumptions, I find market valuations of between $9 and $14 million
each, for patents in leading—and highly competitive—research areas, which include
erythropoietin, colony-stimulating factors, human growth hormone, and hepatitis-B vaccine.
These “protein” patents comprise about 12% of the sample. I also find that in general, these
                                                
40 The final column shows that for α  = 1, WSJ patents impose net costs on rivals averaging $2.3 million, versus
neutral-firm benefits of $2.4 million. Spillovers to rivals may exceed those to neutral firms but be offset by other
costs. Neutral-firm benefits are $1.2 million, $1.9 million, $4.3 million if p = 0.5, and $6.2 million, $9.4 million, and
$21.5 million if p = 0.9.Resources for the Future Austin
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patents generate net spillovers valued from $2 to $4 million per patent per rival firm. The
patentees in my sample usually appropriate less than half of the private returns to their patents. I
also find that neutral biotech firms receive spillovers valued about one-third as highly.
Most of these effects appear to be due to a subset of these patents for innovations in
recombinant DNA or genetic engineering. These patents are valued at between $13 and $21
million and yield $3 to $6 million in spillovers to rivals. A few “seminal” patents—and others
also noted in the WSJ—received much higher valuations and were, atypically, expected to
impose net costs on rival firms. Finally, 88% of the patents are not related to the contested
proteins and generate excess returns that are not significantly different from zero.
That just one-eighth of the patents should have significant economic value is consistent
with earlier research, although here I also explain patent value as a function of content. The
valuations seem rational, in the sense of responding to characteristics—possibly including patent
breadth—that I deemed, a priori, to be desirable. My central estimate of about $17 million in
own value exceeds earlier estimates by more than an order of magnitude. This finding can be
defended by comparing the value of the patents to the total capitalized values of the patent-
holders, and on the basis of the importance of the patents in generating revenues. In my sample,
the firms always held multiple patents on a product by the time they began selling it.
My spillover results are also consistent with earlier empirical research, which shows that
rival firms’ R&D productivity is mutually beneficial. My findings suggest that individual patents
may be a direct pathway for knowledge spillovers and that these, too, can have significant
economic value—my central estimate is about $4 million per rival firm for the more valuable
patents. Except in a few high-profile cases, the market does not seem to treat patents as winner-
take-all prizes. In my current research, I find evidence that even for the WSJ patents, from which
the market appears to expect negative spillovers, patenting by rival firms is slowed only
temporarily.
This research contributes to a broader understanding of the role patents play in firms’
strategic interactions, and in shaping the evolving market structure in biotechnology.
Biotechnology patents—valuable assets with direct and immediate effects on the patentees and
their rivals—seem to merit the importance placed on them by innovating firms.Resources for the Future Austin
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Appendix
Table A1. Top U.S. Biotechnology Firms











1 Genentech 1,289.4 341.7 1 103
2 Amgen 555.8 69.2 2 30
3 Cetus * 283.3 57.6 4 170
4 Genetics Institute 222.1 19.8 9 41
5 Centocor 178.6 62.9 3 18
6 Biogen 164.2 26.7 6 23
7 Chiron 151.7 28.5 5 24
8 Xoma 140.3 6.7 15 13
9 Cambridge Biotech 139.5 4.2 21 5
10 Molecular Biosystems 137.9 5.0 20 7
11 Immunex 94.2 20.9 8 26
12 NeoRx 81.0 6.0 16 26
13 Genzyme 68.1 21.6 7 6
14 Calif. Biotechnology 65.7 13.3 10 12
15 Repligen 47.5 7.6 14 31
16 Synergen 41.2 8.6 12 5
17 Integrated Genetics † 31.6 12.5 11 10
18 Oncogene Scientific ‡ 25.8 5.9 17 0
19 Bio-Technology General 17.4 5.4 19 10
20 Monoclonal Antibodies § 16.3 8.5 13 2
Source: William O’Neil & Co., 12/16/88
* Purchased by Chiron, December 1991
† Merged with Genzyme, August 1989
‡ Prior to 1992 Oncogene licensed patents from other firms only
§ Monoclonal Antibodies merged with Quidel in January 1991Resources for the Future Austin
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3 outside sample. (17 in-sample
patents + 3 outside)
Biogen, Genzyme,
Integrated Genetics
Regulate production of red blood cells;
immunomodulators.
Erythropoietin (EPO) * Amgen, GI,
Integrated Genetics (IntG),




Alternative to blood transfusions in dialysis patients.
Factor VIII * Chiron, Genentech, GI,
2 outside (6+5)
Biogen, IntG Lacking in hemophiliacs. Biotech product
  eliminates HIV risk of natural substitute.
Hepatitis B vaccine * Amgen, Biogen, Genentech, IG,
7 outside (6+8)







Short stature, osteoporosis, renal failure, burns, obesity.
No risk of disease with synthetic hGH.
Imaging MAbs* Centocor, Cetus, Molecular
Biosystems, NeoRx, XOMA
(10+N/A)
Genentech Diagnostic aid. Monoclonal Antibodies (MAbs) are
specific for particular antigens.





(None) Anti-cancer, anti-inflammatory, anti-viral agent;
immunomodulator.





Highly toxic to cancer tumors.
Mediates, stimulates immune response.
Insulin Amgen, Chiron, Genentech,
4 outside (4+6)





Chiron, GI, IntG Activates clot-dissolving enzyme; coronary treatment.





Amgen Wound-healing agent; anti-inflammatory drug.





Scios, Chiron Potential for wound healing, esp. large-area skin grafts.
Platelet-derived
Growth Factor (PDGF)






Chiron Potential therapy for transplant, coronary, osteoarthritis.





(None) Similar to EGF.





(None) Anti-cancer, -inflammatory, -viral agent; immuno-
modulator. Suspected pathogen for acute shock.
† From “Genetically Engineered Human Therapeutic Drugs,” Copsey and Delnatte (1988)
* Two or more in-sample firms in or past Stage III clinical trials by 1992Resources for the Future Austin
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Table A3. Biotechnology Protein Patents noted
 in the Wall Street Journal through 1991
Patent Firm Protein Filed Granted






4703008 Amgen EPO 11/30/8
4
10/27/87
4710463 Biogen Hepatitis B vaccine 3/31/82 12/1/87
4727138 Genentech Interferon-gamma 9/11/85 2/23/88








4766106 Cetus Interleukin-2 1/25/88 8/23/88
4810643 Amgen Colony stimulating
factor (CSF)
3/3/86 3/7/89
4853330 Genentech TPA 4/21/88 8/1/89
4868112 Genetics
Institute











5026839 Synergen Fibroblast growth
factor
4/5/90 6/25/91
5057598 Centocor Mab for septic
shock
2/1/89 10/15/91
The patent sample includes another 9 WSJ patents not associated with any of 17 proteins.